Danaher shareholders worth over $400 billion in assets called on Danaher to audit and disclose the cost of production for the GeneXpert test cartridges and adjust their prices accordingly to ensure access to these lifesaving tests. In a letter to Danaher, they said, “Such audits are critical to ensure that Danaher is not making profits on the sales of these life-saving tests and remains committed to optimal healthcare access for people living in low and middle-income countries.”
